ArticleDiscover oncology2026
ASAP3 activates the NF-κB signaling pathway to promote the progression of esophageal squamous cell carcinoma.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundEsophageal squamous cell carcinoma (ESCC) is one of the most common malignancies worldwide. Despite advances in diagnosis and treatment, the lack of effective therapeutic targets continues to limit improvements in patient outcomes. ASAP3 has been implicated in tumor progression; however, its role and underlying mechanisms in ESCC remain unclear.
methodsParaffin-embedded ESCC tissues were analyzed by immunohistochemistry to evaluate the expression of ASAP3, NEMO, p65, phosphorylated p65 (p-p65), and MMP9 and their associations with clinicopathological parameters. In vitro, ASAP3 was silenced to assess its effects on ESCC cell proliferation, migration, and invasion and to explore the underlying mechanisms. In vivo, the role of ASAP3 in ESCC growth was validated using a mouse xenograft model, with tumor size and volume measured and changes in ASAP3, NEMO, p65, and p-p65 expression further analyzed.
resultsClinicopathological analysis showed that elevated ASAP3, NEMO, p65, p-p65, and MMP9 expression in ESCC tissues was associated with poor prognosis. In vitro, ASAP3 knockdown inhibited the proliferation, migration, and invasion of KYSE450 cells. In vivo, ASAP3 silencing suppressed xenograft tumor growth and reduced tumor proliferative activity. Mechanistically, ASAP3 downregulation decreased NEMO expression and p65 phosphorylation, thereby suppressing ESCC cell proliferation, migration, and invasion.
conclusionsCollectively, ASAP3 may promote ESCC progression by interacting with NEMO and activating NF-κB signaling. These findings suggest that ASAP3 functions as an oncogenic driver and may serve as a potential biomarker in ESCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.